Global Dermatitis Drugs Market By Drug Class (PDE-4 Inhibitor, Corticosteroid, Biologics) By Mode of Administration (Topical, Injectable, and Oral), By Disease Indication(Atopic Dermatitis, Contact Dermatitis, and Others), By Distribution Channel (Hospital, Retail, and Online), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2023-2032

Report Overview

Global Dermatitis Drugs Market size is expected to be worth around USD 23,265 Mn by 2032 from USD 10,315 Mn in 2022, growing at a CAGR of 8.7% during the forecast period from 2022 to 2032.

Due to an increase in atopic dermatitis cases and prevalence, the global market for atopic dermatitis medications is expected to expand at a rapid rate over the forecast period. A rise in cases of atopic dermatology has led to an increase in the demand for effective treatments such as cyclosporine or atopic antihistamine. Programs to raise awareness about atopic dermatology medications are being implemented by governments in both developed and developing nations.

The demand for better treatments for atopic skin diseases is also rising due to the development of new drugs that treat atopic dermatology and an increase in clinical trials. The increase in investment made by companies to develop new treatments for atopic skin diseases is boosting the market. Pfizer and Sanofi have both introduced drugs to treat atopic dermatitis. These drugs were approved by the U.S. FDA

Market Scope

Atopic dermatitis refers to a condition where the skin becomes dry, red, itchy, and bumpy. This is just one type of dermatitis. It causes damage to the skin’s barrier function. The skin becomes more sensitive, more prone to infection, and more dry. The body is not affected by atopic dermatitis. This does not mean that your skin is infected or dirty. It also doesn’t make you more ill.

There are many treatments that can be used to manage these symptoms. There are treatments that can help manage the symptoms. Market growth is expected to be driven by the growing prevalence of atopic dermatology, the strong pipeline, the emergence of biologics and untapped opportunities. Atopic dermatitis is steadily increasing in prevalence.

By Drug Class Analysis

The global dermatology market is dominated by biologics

Based on drug class, the market dermatitis is segmented into PDE-4 Inhibitor, Corticosteroid, Biologics, Calcineurian Inhibitors (Tacrolimus, Pimecrolimus), Skin Barrier Emollients, CNI Immunosuppressant’s, Others. Due to increased injectable product use such as Dupilumab, Tofacitinib, Ruxolitinib, and other injectable biologics are currently under clinical trial. Biologics will likely change the landscape for AD therapeutics in the near future.

To meet this high unmet demand, they are being studied for pediatric patients. Pediatric patients with AD have very few options. Dupilumab is one of the programs that aims to develop AD drugs for children. This program is designed to improve clinical research. This is due to increased awareness about the available treatments and the rise in government initiatives to make it more affordable. The segment is also experiencing new product launches and greater adoption of biologic drugs in multiple regions.

By Mode of Administration

Injectable mode of administration is dominating the market 

By Mode of Administration it segmented into Topical, Injectable, and Oral. With a market share of more than 40.0%, the injectable segment was the dominant segment in 2022. It is expected to continue its dominance during the forecast period. New launches in JAK inhibitors are expected to drive the second-highest growth rate for the oral segment during the forecast period.

These drugs are mainly administered via the oral route. In extreme cases where the disease has spread to large areas or if there is a complication with any other treatments, oral corticosteroids may be prescribed. Oral medications include azathioprine (cyclosporine), methotrexate and mycophenolate Mofetil.

Distribution Channel Analysis

By distribution channel the market leader in distribution channel was the hospital pharmacy segment in 2022. This trend is expected continue through the forecast period due to the high prevalence of atopic dermatology, rising prices of drugs and increasing income levels of low and middle-class families.

Key Market Segments

Based on Drug Class

• PDE-4 Inhibitor
• Corticosteroids
• Biologics
• Calcineurin Inhibitors
• Tacrolimus
• Pimecrolimus
• SkinBarrier Emollients
• CNI Immunosuppressant’s
• Others
• Retail

Based on the Mode of Administration 

• Topical
• Injectable
• Oral

Based on Disease Indication analysis

• Atopic Dermatitis
• Contact DermatitisOthers

Based on Distribution Channel 

• Online Platforms
• Hospitals

Market Dynamics

Drivers

Rise in incidence of atopic dermatitis infection 

Chronic skin inflammation that results in skin reddening and itchy skin is known as Dermatitis. Treatment may be required for white fluid discharge from the affected area. Atopic dermis is most common in childhood, and can become more severe as we age. Atopic dermatitis can be caused by genetic disorders, environmental exposure, immune system dysfunction, or skin permeability problems. The treatment of dermatological conditions, particularly atopic dermatitis, has been revolutionized by the use of biologic drugs.

Rise in demand for biologics propelling

Biopharmaceutical giants are investing heavily in product development, mergers & acquisitions, strategic collaborations, and biologic product design. The biologics have shown positive results in atopic dermatitis, which has led to an improvement in the quality of life. The overall demand for biologics for atopic dermatology has increased. This trend will likely continue over the next few years. To date, only one biologic product has been approved to treat atopic dermatology. Many others are currently in phase II clinical trials, and will likely be approved in the near future.

Restraints

The easy availability of costly treatment and the poor reimbursement policies in developing countries around the world are expected to be major barriers to the growth in the dermatitis Atopica market.

However, allergic reactions to off-label treatments and expiry of patents can hinder the market’s growth over the forecasted atopic dermatitis forecast period. Topical steroids that last less than four weeks are usually safe and hassle-free. Problems could arise from long-term use of topical steroids or repeated high doses of stronger steroids. The main problem is prolonged use of potent steroids. Side effects of mild topical steroids are rare. Topical steroids can have systemic or local side effects. Systemic refers a problem that affects all individuals, while local refers only to a particular area of the skin as a result it will affect the growth of this market.

Opportunity

Anacor Pharmaceuticals Inc, and Regeneron Pharmaceuticals Inc. leading the Global Dermatitis Drugs Market

Global dermatitis drug market is fragmented. There are many manufacturers involved in marketing and producing generic drugs. Dupilumab (sold under the brand Dupixent by Regeneron Pharmaceuticals & Sanofi) has revolutionized the face of dermatitis treatment. It is now widely accepted and provides a powerful and effective way to treat the symptoms of dermatitis. It is an interleukin-4 inhibitor, which generated around US$ 922 million in revenue by the end 2018.

Another key product in the dermatitis drug industry, Eucrisa, is another product that Anacor Pharmaceuticals, Inc. has seen a promising rise over the last three years. The number of new players in the market will increase by 2026 due to ongoing clinical trials of new molecules and the green signal from the USFDA for the approval of dermatitis medications in the U.S.

Trends

Companies are investing in R&D to create new products for atopic dermatitis. 

This market is very lucrative.Major companies are expected to see revenue growth in the future due to the increasing number of drugs that have passed the clinical trials phase 2b.Galderma, for instance, announced in April 2021 phase 2b results in uncontrolled atopic dermatology patients with Nemolizumab. Pfizer declared that the under-development drug abrocitinib was not superior to the Sanofi treatment Dupixent in March 2021. There is a need for oral medications among patients with atopic dermatitis. Abrocitinib is a Janus kinase 1 inhibitor. Korsuva by Cara Therapeutics is a phase 2 oral medication for pruritus due to atopic skin diseases.

COVID-19 Impact Analysis

The pandemic has caused a decline in output and profit for every industry. The market for treating atopic dermatology has seen a significant impact due to the infrequent hospital visits of patients. 

The global atopic dermatology market is expected to suffer from the COVID-19 pandemic. People are still experiencing problems with the coronavirus, which continues to disrupt their lives worldwide. It has affected everything from their social interactions to how much they receive medical care and how they see the outside world.  Tele dermatology has seen a rise in popularity during this crisis, when most patients receive generalized care and/or additional consultative treatments without visiting a doctor. Patients with atopic dermatology should continue to receive their current treatment. They should consult their doctors before discontinuing their oral and biologic therapy.

According to the National Eczema Association the risk of serious life-threatening complications in eczema patients is not increased by the coronavirus crisis. Atopic dermatitis sufferers are more likely to experience anxiety and depression. Patients also tend to have higher occurrences at the emergency department. These factors will likely accelerate the growth of the global market for atopic dermatology. Patients with coronavirus are not affected by atopic dermatitis.

Atopic diseases in adults are more at risk for lower respiratory tract infections and upper respiratory tract infections than those who don’t have atopic conditions. Patients infected by corona virus did not experience any complications during their infection. Patients with atopic dermatology are reported to be able to receive safe and effective treatment with dupilumab. Due to sanitary restrictions, market teledermatology increased during the COVID-19 epidemic.

Regional Analysis

North America held the largest market share of the atopic dermatology market by region in 2021. It is expected to continue its dominance over the forecast period. 

This can be attributed to the increasing prevalence of atopic skin diseases, increased awareness and treatment options, and advances in the atopic dermatology industry. It is also due to a well-established healthcare system and the early adoption of new medications. According to the 2022 National Eczema Association report, nearly 40% of Americans have severe or moderate atopic dermatitis. The highest rate of atopic dermatitis market growth was seen in Asia-Pacific, which is due to the strong presence and development of healthcare technology, large patient population, and rising healthcare expenditure.

According to American Journal of Managed Care in 2017, up to 15,000,000 Americans were affected by atopic dermatology. Atopic dermatitis is common in infants, with 10% to 20% of them suffering from it. Nearly half of those affected will be able to overcome the condition, and many others will see significant improvements as they age. Both males and women can suffer from atopic dermatitis. It is more common in those with a family history of allergies, asthma, or food allergies. Atopic dermatitis may appear anywhere on the skin. It can be found in teens and adults on the hands, necks, inner elbows and feet.

Key Regions

• North America
• The US
• Canada
• Mexico

• Eastern Europe
• Russia
• Poland
• The Czech Republic
• Greece
• Rest of Eastern Europe

• Western Europe
• Germany
• France
• The UK
• Spain
• Italy
• Portugal
• Ireland
• Austria
• Switzerland
• Benelux
• Nordic
• Rest of Western Europe

• APAC
• China
• Japan
• South Korea
• India
• Australia & New Zealand
• Indonesia
• Malaysia
• Philippines
• Singapore
• Thailand
• Vietnam
• Rest of APAC

• Latin America
• Brazil
• Colombia
• Chile
• Argentina
• Costa Rica
• Rest of Latin America

• Middle East & Africa
• Algeria
• Egypt
• Israel
• Kuwait
• Nigeria
• Saudi Arabia
• South Africa
• Turkey
• United Arab Emirates
• Rest of MEA

Market Share & Key Players Analysis

Atopic dermatitis is on the rise. According to Acta Derm Venereologica Journal 2020, the prevalence rate of atopic skin diseases was between 17.1% and 10.2% in Europe, and 22.6% and 0.96% respectively in children. It is the most severe skin condition and has been classified as the most expensive. Sanofi, for example, announced the U.S.

FDA approval in June 2022 of Dupixent, (dupilumab), for children aged 6 to 5 years with atopic dermatitis. AbbVie Inc. approved RINVOQ (upadacitinib), by the U.S. FDA in January 2022 for severe atopic dermatitis management in children aged over 12 years and adults. Patients who have not responded to previous treatments with pills or injections may be recommended to try RINVOQ.

Recent Development

• In April 2021 AbbVie announced that it would extend sNDA to cover the review of RINVOQ treatment for atopic dermatology adolescent patients and adults. 
• In April 2021 the PDUFA was extended to the third quarter and Pfizer acquired ReViral, a private, clinical-stage Biopharmaceutical company. This acquisition further shows Pfizer’s commitment towards pioneering science through both its own expertise and collaboration with innovative companies. The goal is to bring breakthroughs to patients with severe infectious diseases. 
• Between 2020 and 2030, the AD market will experience significant growth due to the introduction of many pipeline agents such as IL and JAK inhibitors. There will also be topical treatments for mild to moderate AD. The new entrants to the AD market will offer more options for patients of all ages and severity. 
• Dupixent (dupilumab), will remain the market player leader, with peak sales estimated for 2030. It is the standard in the treatment of mild to severe AD. 
• KOLs expressed uniqueness for the end-stage agent etrasimod, which is anti-OX40 mAb, and another is sphingosine-1-phosphate receptor-1 (S1PR) modulator an, rocatinlimab (KHK4083) due to their innovative mechanisms of action and the innovation they would bring to the market; if approved, they would both be the first in their respective classes. 
• AD’s most pressing unmet needs are CHE, long-term disease management, and better treatment options. There is also a lack of options for chronic hand eczema (CHE) that can be treated. 

Market Key Players

The market’s competitive rivalry is expected to continue to be high over the forecast period. This can be attributed in part to the anticipated launch new products during that period. Partnerships are being formed to commercialize and develop new products. Collaborations are common between players. The market’s highly lucrative nature amid the pandemic is drawing new players and increasing competition for established companies. AbbVie, for example, announced in April 2021 that it would extend sNDA to cover the review of RINVOQ treatment for atopic dermatology adolescent patients and adults. The PDUFA was extended to the third quarter of 2021.

The market’s competitive rivalry is expected to continue to be high over the forecast period. This can be attributed in part to the anticipated launch new products during that period. Partnerships are being formed to commercialize and develop new products. Collaborations are common between players. The market’s highly lucrative nature amid the pandemic is drawing new players and increasing competition for established companies.

The following are some of the major players in the global market for atopic dermatitis medications:

• AbbVie Inc.
• Aclaris Therapeutics
• Amgen
• Anacor Pharmaceutical Inc.
• Arena Pharmaceuticals
• Astellas Pharma Inc.
• Cara Therapeutics
• Dermavant
• Eli Lilly
• Galderma
• Incyte
• Japan Tobacco
• Kyowa Kirin
• Medimetriks
• Otsuka Pharmaceutical
• RAPT Therapeutics
• Regeneron Pharmaceuticals, Inc
• Sanofi S.A
• Torii Pharmaceuticals
• Mylan N.V.
• Pfizer Inc.
• LEO Pharma A/S
• Novartis AG
• Bausch Health
• Teva Pharmaceutical Industries Ltd.
• Vanda Pharmaceuticals
• Other Key Players

Report Scope